1μg (R: reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | CD267 antigen; CD267; CVID; CVID2; FLJ39942; MGC133214; TACI; TACIMGC39952; TNFRSF13B; TNFRSF14B; Transmembrane activator and CAML interactor; tumor necrosis factor receptor 13B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor superfamily, member 13B |
Accession | O14836-1 |
Amino Acid Sequence | Ser2-Thr166 with Human IgG1 Fc at C-Terminus |
Expression System | HEK293 |
Molecular Weight | 33-40kDa &43-55kDa (Reducing) |
Purity | > 95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | Human IgG1 Fc |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4, 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | 1.Xia, X.-Z. et al. (2000) J. Exp. Med. 192:137. |
Background
TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily. TACI is a type III membrane protein with an extracellular N‑terminus in the absence of a cleaved signal sequence. Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA have both been shown to bind APRIL and BAFF, members of the TNF ligand superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Analogous to BCMA, data suggests that TACI may play an important role in B cell development, function and regulation. The expression of APRIL, BCMA and TACI were observed to be involved in extracellular signal-regulated kinase (ERK)1/2 activation in A549 cells.
Picture
Picture
SDS-PAGE
ELISA
Immobilized TACI/CD267/TNFRSF13B Fc Chimera Protein, Human (Cat. No. UA011118) at 1.0μg/mL (100μL/well) can bind Biotinylated BAFF Protein, human with EC50 of 1.47-2.12 ng/mL.
